Crossmark

Long-term survival benefit of atezolizumab/bevacizumab treatment in unresectable HCC patients

Crossref DOI link: https://doi.org/10.1007/s12072-025-10918-z

Published Online: 2025-09-27

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Peck-Radosavljevic, Markus https://orcid.org/0000-0002-0597-2728
License Information

Text and Data Mining valid from 2025-09-27

Version of Record valid from 2025-09-27
More Information

Article History

Received: 27 July 2025

Accepted: 11 September 2025

First Online: 27 September 2025

Free to read: This content has been made available to all.